Lifeboat Foundation

This has been announced by Pulsar Fusion, the company responsible for its manufacture. The name Pulsar Fusion may not be familiar to most people, but it may soon achieve an unprecedented milestone in the world of nuclear fusion. Although there are many steps to take, Pulsar Fusion has been working since 2013 to achieve a rocket that breaks all known barriers to date.

Science_Hightech — operanewsapp.

Researchers think they understand the conditions which see the precious stones erupt to the Earth’s surface from far below where they are formed.

👉 Invest in Blue-chip Art by signing up for Masterworks: https://www.masterworks.art/anastasi.
Purchase shares in great masterpieces from Pablo Picasso, Banksy, Andy Warhol, and more.
See important Masterworks disclosures: https://www.masterworks.com/about/disclaimer?utm_source=anas…subscriber.

Mentioned Videos:
AI designing Computer Chips: https://youtu.be/NeHgMaIkPuY
Deepmind AI made a Breakthrough in Math: https://youtu.be/DU6WINoehrg.

Continue reading “DeepMind’s New AI made a Breakthrough in Computer Science!” »

One of the oldest known molecules, the ribosome, creates proteins based on a copy of the genetic code found in the genome, known as mRNA. Scientists have believed that the ribosome performed the same type of work with all mRNA, like a standardized assembly line that it did not regulate on its own. However, researchers from the University of Copenhagen have discovered this is not the case.

Their findings are published in the journal Developmental Cell in an article entitled “Ribosomal RNA 2′-O-methylation dynamics impact cell fate decisions.”

“It has long been known that there are different types of ribosomes. But it has been assumed that no matter what mRNA you give the ribosome, it will produce a protein. But our results suggest that different types of ribosomes produce specific proteins,” says Anders H. Lund, professor at the Biotech Research and Innovation Center at the University of Copenhagen.

Recombinant adeno-associated virus (rAAV) vectors are a cornerstone of genetic medicine. These hollow virus particles are used to deliver commercial gene therapies like Glybera and Luxturna, as well as many other candidates still in development.

Despite this, the biopharmaceutical industry has yet to find the most effective way of making rAAV vectors at scale. McKinsey analysts recently described vector production as one of the major challenges faced by gene therapy developers. And the situation is only going to get worse as the gene therapy market evolves and begins developing products for larger patient populations.

“With a shift beyond ultra-rare indications, viral-vector manufacturing requires rapid expansion to be able to address various diseases in the commercial space,” the analysts wrote, adding, “The broader application of viral vector-based gene therapies (for example, to more common diseases) requires higher yields and lower cost of goods (COGs).”

A new artificial intelligence model can predict people’s risk of multiple sclerosis years before diagnosis, potentially enabling quicker treatment, according to research revealed at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. Another breaking study demonstrates how machine learning can help detect lab samples contaminated with intravenous fluids—a finding that could reduce lab errors that delay diagnosis and raise healthcare costs.

Taken together, the results highlight key advances in the use of artificial intelligence and machine learning to improve patient care.

AI model harnesses patient data to predict multiple sclerosis risk.

Dr. James East explains what causes Barrett’s esophagus, who is at risk, how it’s diagnosed and treated, and how you can reduce your risk of developing the condition.

SpaceX just loaded propellant into two of its Starship Super Heavy booster prototypes as part of a prelaunch test campaign.